Effect of manshuailing oral liquid on left ventricular diastolic dysfunction in patients with heart disease of Xin-Shen Yang deficiency type.
- Author:
Ding-you YANG
1
;
Shi-wen WANG
;
Qing-lei ZHU
Author Information
- Publication Type:Clinical Trial
- MeSH: Aged; Cardiac Output, Low; drug therapy; physiopathology; Diagnosis, Differential; Drugs, Chinese Herbal; therapeutic use; Female; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Phytotherapy; Ventricular Dysfunction, Left; drug therapy; physiopathology; Yang Deficiency; drug therapy
- From: Chinese Journal of Integrated Traditional and Western Medicine 2003;23(5):344-346
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of Manshuailing Oral Liquid (MSL) on left ventricular diastolic dysfunction (LVDD) in patients with heart disease.
METHODSNinety patients with LVDD were randomly divided into the conventional treated group (Group A, treated by conventional treatment with western drugs of cardiotonic, diuretic, coronary dilator, etc.) and the Chinese drug treated group (Group B, treated by conventional treatment plus MSL 2 times a day, 100 ml each time), 45 in each group. After 4 months treatment, the total heart failure coefficient (HFC) and cardiac functions were re-determined.
RESULTSAfter treatment, in both groups, the HFC lowered significantly (P < 0.05 or P < 0.01), the left ventricular peak velocity of early diastolic rapid filling (Emas) quickened, the left atrial systolic peak velocity (Amas) slowed down and Emas/Amas (E/A) enhanced, the isovolumetric relaxation time shortened. However, comparison between the two groups showed significant difference (P < 0.05) in either item, Group B was superior to Group A (P < 0.05). In the 62 patients with mixed heart failure, i.e. both systolic and diastolic dysfunction of left ventricle, Group B was superior to Group A in increasing ejection fraction, cardiac output and thickening rate of left ventricular posterior wall (P < 0.05).
CONCLUSIONMSL could improve the heart function of patients with LVDD, and alleviate their clinical symptoms.